Long Fu Xi1, Mark Schiffman2, Laura A Koutsky2, James P Hughes2, Rachel L Winer2, Constance Mao2, Ayaka Hulbert2, Shu-Kuang Lee2, Zhenping Shen2, Nancy B Kiviat2. 1. Department of Pathology (LFX, AH, ZS, NBK) and Department of Obstetrics and Gynecology (CM), School of Medicine, and Department of Epidemiology (LFX, LAK, RLW, SKL) and Department of Biostatistics (JPH), School of Public Health and Community Medicine, University of Washington, Seattle, WA; Division of Cancer Epidemiology and Genetics (MS), National Cancer Institute, Bethesda, MD. longfu@u.washington.edu. 2. Department of Pathology (LFX, AH, ZS, NBK) and Department of Obstetrics and Gynecology (CM), School of Medicine, and Department of Epidemiology (LFX, LAK, RLW, SKL) and Department of Biostatistics (JPH), School of Public Health and Community Medicine, University of Washington, Seattle, WA; Division of Cancer Epidemiology and Genetics (MS), National Cancer Institute, Bethesda, MD.
Abstract
BACKGROUND: Data on clinical outcomes of infection with variants of oncogenic human papillomavirus (HPV) types other than HPV16 and HPV18 are rare. We investigated intratypic variations in non-HPV16/18 oncogenic types and their corresponding relationships with cervical intraepithelial neoplasia grades 2-3 (CIN2/3). METHODS: Study subjects were women who were positive for one or more of 11 non-HPV16/18 oncogenic types. Subjects were followed every six months for two years for detection of HPV and cervical lesions. Variant lineages were defined by sequencing the 3' part of the long control region and the entire E6/E7 region of HPV genome. Lineage-associated risk of CIN2/3 was assessed using logistic regression with generalized estimating equations. RESULTS: A total of 4591 type-specific HPV infections among 2667 women were included in the analysis. The increase in risk of CIN2/3 was statistically significant for women with HPV31 A or B compared with C variants, HPV33 A1 compared with B variants, HPV45 A3 or B2 compared with B1 variants, HPV56 B compared with A2 variants, and HPV58 A1 or A3 compared with C variants. For these five types, the adjusted odds ratio associated with CIN2/3 was 2.0 (95% confidence interval [CI] = 1.5 to 2.6) for infections with single-type high-risk (HR) variants, 1.7 (95% CI = 1.0 to 2.7) for infections with two or more types but only one HR variant, and 5.3 (95% CI = 3.1 to 8.4) for infections with HR variants of two or more types as compared with those with single-type non-HR variants. The likelihood of CIN2/3 was similar for women with HPV16 infection and for those with HPV58 A1 variant infection. CONCLUSIONS: These findings suggest that for a given HPV type, intratypic nucleotide changes may alter phenotypic traits that affect the probability of neoplasia.
BACKGROUND: Data on clinical outcomes of infection with variants of oncogenic human papillomavirus (HPV) types other than HPV16 and HPV18 are rare. We investigated intratypic variations in non-HPV16/18 oncogenic types and their corresponding relationships with cervical intraepithelial neoplasia grades 2-3 (CIN2/3). METHODS: Study subjects were women who were positive for one or more of 11 non-HPV16/18 oncogenic types. Subjects were followed every six months for two years for detection of HPV and cervical lesions. Variant lineages were defined by sequencing the 3' part of the long control region and the entire E6/E7 region of HPV genome. Lineage-associated risk of CIN2/3 was assessed using logistic regression with generalized estimating equations. RESULTS: A total of 4591 type-specific HPV infections among 2667 women were included in the analysis. The increase in risk of CIN2/3 was statistically significant for women with HPV31 A or B compared with C variants, HPV33 A1 compared with B variants, HPV45 A3 or B2 compared with B1 variants, HPV56 B compared with A2 variants, and HPV58 A1 or A3 compared with C variants. For these five types, the adjusted odds ratio associated with CIN2/3 was 2.0 (95% confidence interval [CI] = 1.5 to 2.6) for infections with single-type high-risk (HR) variants, 1.7 (95% CI = 1.0 to 2.7) for infections with two or more types but only one HR variant, and 5.3 (95% CI = 3.1 to 8.4) for infections with HR variants of two or more types as compared with those with single-type non-HR variants. The likelihood of CIN2/3 was similar for women with HPV16infection and for those with HPV58 A1 variant infection. CONCLUSIONS: These findings suggest that for a given HPV type, intratypic nucleotide changes may alter phenotypic traits that affect the probability of neoplasia.
Authors: P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple Journal: J Clin Microbiol Date: 2000-01 Impact factor: 5.948
Authors: Mark Schiffman; Ana Cecilia Rodriguez; Zigui Chen; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Rob Desalle; Brian Befano; Kai Yu; Mahboobeh Safaeian; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Diane Solomon; Philip E Castle; Robert D Burk Journal: Cancer Res Date: 2010-03-30 Impact factor: 12.701
Authors: Helen Trottier; Salaheddin Mahmud; Maria Cecilia Costa; João P Sobrinho; Eliane Duarte-Franco; Thomas E Rohan; Alex Ferenczy; Luisa L Villa; Eduardo L Franco Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-07 Impact factor: 4.254
Authors: Anil K Chaturvedi; Leann Myers; Ansley F Hammons; Rebecca A Clark; Kathleen Dunlap; Patricia J Kissinger; Michael E Hagensee Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-10 Impact factor: 4.254
Authors: Patti E Gravitt; Leen Jan van Doorn; Wim Quint; Mark Schiffman; Allan Hildesheim; Andrew G Glass; Brenda B Rush; Jared Hellman; Mark E Sherman; Robert D Burk; Sophia S Wang Journal: J Clin Microbiol Date: 2007-08-15 Impact factor: 5.948
Authors: Paul K S Chan; Chuqing Zhang; Jong-Sup Park; Karen K Smith-McCune; Joel M Palefsky; Lucia Giovannelli; Francois Coutlée; Samantha Hibbitts; Ryo Konno; Wannapa Settheetham-Ishida; Tang-Yuan Chu; Annabelle Ferrera; María Alejandra Picconi; Federico De Marco; Yin-Ling Woo; Tainá Raiol; Patricia Piña-Sánchez; Jeong-Hoon Bae; Martin C S Wong; Mike Z Chirenje; Tsitsi Magure; Anna-Barbara Moscicki; Alison N Fiander; Giuseppina Capra; Eun Young Ki; Yi Tan; Zigui Chen; Robert D Burk; Martin C W Chan; Tak-Hong Cheung; David Pim; Lawrence Banks Journal: Int J Cancer Date: 2012-11-29 Impact factor: 7.396
Authors: Paul K S Chan; Ching Wan Lam; Tak Hong Cheung; William W H Li; Keith W K Lo; May Y M Chan; Jo L K Cheung; Li Ying Xu; Augustine F Cheng Journal: J Infect Dis Date: 2002-08-05 Impact factor: 5.226
Authors: Tsung-chieh Jane Fu; Long Fu Xi; Ayaka Hulbert; James P Hughes; Qinghua Feng; Stephen M Schwartz; Stephen E Hawes; Laura A Koutsky; Rachel L Winer Journal: Int J Cancer Date: 2015-05-29 Impact factor: 7.396
Authors: Sara L Bissett; Anna Godi; Maxime J J Fleury; Antoine Touze; Clementina Cocuzza; Simon Beddows Journal: J Virol Date: 2015-05-20 Impact factor: 5.103
Authors: Anna Godi; Alessandra Facchetti; Sara L Bissett; Clementina Cocuzza; Elizabeth Miller; Simon Beddows Journal: J Virol Date: 2015-12-30 Impact factor: 5.103
Authors: Long Fu Xi; Mark Schiffman; Laura A Koutsky; James P Hughes; Ayaka Hulbert; Zhenping Shen; Denise A Galloway; Nancy B Kiviat Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: Tsung-chieh Jane Fu; James P Hughes; Qinghua Feng; Ayaka Hulbert; Stephen E Hawes; Long Fu Xi; Stephen M Schwartz; Joshua E Stern; Laura A Koutsky; Rachel L Winer Journal: Sex Transm Dis Date: 2015-12 Impact factor: 2.830
Authors: Ariana Harari; Zigui Chen; Ana Cecilia Rodríguez; Allan Hildesheim; Carolina Porras; Rolando Herrero; Sholom Wacholder; Orestis A Panagiotou; Brian Befano; Robert D Burk; Mark Schiffman Journal: J Infect Dis Date: 2015-10-30 Impact factor: 5.226
Authors: Zigui Chen; Mark Schiffman; Rolando Herrero; Rob DeSalle; Kathryn Anastos; Michel Segondy; Vikrant V Sahasrabuddhe; Patti E Gravitt; Ann W Hsing; Paul K S Chan; Robert D Burk Journal: Virology Date: 2018-01-11 Impact factor: 3.616